- Home
- FTRE vs CSTL Comparison
FTRE vs CSTL Comparison
Compare FTRE & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRE
- CSTL
- Stock Information
- Founded
- FTRE 1996
- CSTL 2007
- Country
- FTRE United States
- CSTL United States
- Employees
- FTRE N/A
- CSTL N/A
- Industry
- FTRE Medical Specialities
- CSTL Medical Specialities
- Sector
- FTRE Health Care
- CSTL Health Care
- Exchange
- FTRE Nasdaq
- CSTL Nasdaq
- Market Cap
- FTRE 701.9M
- CSTL 697.9M
- IPO Year
- FTRE N/A
- CSTL 2019
- Fundamental
- Price
- FTRE $10.20
- CSTL $21.62
- Analyst Decision
- FTRE Hold
- CSTL Strong Buy
- Analyst Count
- FTRE 9
- CSTL 6
- Target Price
- FTRE $12.06
- CSTL $37.67
- AVG Volume (30 Days)
- FTRE 1.9M
- CSTL 423.4K
- Earning Date
- FTRE 11-07-2025
- CSTL 11-03-2025
- Dividend Yield
- FTRE N/A
- CSTL N/A
- EPS Growth
- FTRE N/A
- CSTL N/A
- EPS
- FTRE N/A
- CSTL N/A
- Revenue
- FTRE $2,733,500,000.00
- CSTL $346,269,000.00
- Revenue This Year
- FTRE N/A
- CSTL N/A
- Revenue Next Year
- FTRE N/A
- CSTL N/A
- P/E Ratio
- FTRE N/A
- CSTL N/A
- Revenue Growth
- FTRE N/A
- CSTL 20.40
- 52 Week Low
- FTRE $3.97
- CSTL $14.59
- 52 Week High
- FTRE $25.28
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- FTRE 62.69
- CSTL 50.19
- Support Level
- FTRE $9.42
- CSTL $22.54
- Resistance Level
- FTRE $10.57
- CSTL $24.74
- Average True Range (ATR)
- FTRE 0.64
- CSTL 1.14
- MACD
- FTRE -0.09
- CSTL -0.28
- Stochastic Oscillator
- FTRE 48.26
- CSTL 28.93
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.